NCT01772472 2025-07-22A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)Hoffmann-La RochePhase 3 Completed1,486 enrolled 37 charts 1 FDA